|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...54555657585960616263646566» |
- ||||| New P2 trial: A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci (clinicaltrials.gov) - Jan 25, 2012
P2, N=103, Completed, Sponsor: Affinium Pharmaceuticals, Ltd
- || New P3 trial: Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis (clinicaltrials.gov) - Jan 23, 2012
P3, N=400, Recruiting, Sponsor: All India Institute of Medical Sciences, New Delhi
- | New P1/2 trial: Effect of Xylitol on Oral Microbiota in Children (clinicaltrials.gov) - Jan 23, 2012
P1/2, N=80, Not yet recruiting, Sponsor: Kuwait University
- Kineret (anakinra) / SOBI
New P2 trial: Anakinra as a Treatment for Hydradenitis Suppurativa (clinicaltrials.gov) - Jan 23, 2012
P2, N=6, Completed, Sponsor: University of California, San Francisco
- doripenem / Generic mfg.
Enrollment change: Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients (clinicaltrials.gov) - Jan 22, 2012
P4, N=12, Completed, Sponsor: Gary E. Stein, Pharm.D.
N=24 --> 12
- Clinical: EHEC-PEG: Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis (clinicaltrials.gov) - Jan 22, 2012
P=N/A, N=33, Completed, Sponsor: Universitätsklinikum Hamburg-Eppendorf
- | AZD5847 / AstraZeneca
New P2 trial, P2a data: Phase 2a EBA Trial of AZD5847 (clinicaltrials.gov) - Jan 22, 2012
P2, N=75, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- doripenem / Generic mfg.
Trial completion: Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients (clinicaltrials.gov) - Jan 22, 2012
P4, N=12, Completed, Sponsor: Gary E. Stein, Pharm.D.
N=24 --> 12 Recruiting --> Completed
- Cubicin (daptomycin) / Merck (MSD)
New P3 trial: DAVASAB: Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia (clinicaltrials.gov) - Jan 19, 2012
P3, N=10, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
- ||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
New P2 trial: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) (clinicaltrials.gov) - Jan 18, 2012
P2, N=692, Completed, Sponsor: Merck Sharp & Dohme Corp.
- Trial withdrawal: Vitamin D in Active Tuberculosis (TB) Study (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=0, Withdrawn, Sponsor: Atlanta VA Medical Center
Recruiting --> Completed Terminated --> Withdrawn
- Enrollment change: Vitamin D in Active Tuberculosis (TB) Study (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=0, Withdrawn, Sponsor: Atlanta VA Medical Center
Terminated --> Withdrawn N=80 --> 0
- meropenem / Generic mfg.
Trial initiation date: Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children (clinicaltrials.gov) - Jan 16, 2012
P4, N=30, Completed, Sponsor: Joseph Kuti
N=80 --> 0 Initiation date: Sep 2011 --> Feb 2012
- HEOR: Impact of a Telenursing Service on Satisfaction and Health Outcomes of Children With Inflammatory Rheumatic Diseases (clinicaltrials.gov) - Jan 16, 2012
P=N/A, N=48, Recruiting, Sponsor: University of Applied Sciences of Western Switzerland
- Trial completion: Long Term Follow-up of Patients With Group A Streptococcal Infection Originating From the Genital Tract (clinicaltrials.gov) - Jan 16, 2012
P=N/A, N=61, Completed, Sponsor: Hadassah Medical Organization
Initiation date: Sep 2011 --> Feb 2012 Recruiting --> Completed
- | Enrollment change, IO biomarker: AVDAPT: L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) (clinicaltrials.gov) - Jan 16, 2012
P3, N=200, Completed, Sponsor: Menzies School of Health Research
Recruiting --> Completed N=444 --> 200
- | Trial completion, IO biomarker: AVDAPT: L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB) (clinicaltrials.gov) - Jan 16, 2012
P3, N=200, Completed, Sponsor: Menzies School of Health Research
N=444 --> 200 Recruiting --> Completed
- New P2 trial: New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study (clinicaltrials.gov) - Jan 15, 2012
P2, N=40, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
- ||||||| Trial completion: Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years (clinicaltrials.gov) - Jan 12, 2012
P3, N=344, Completed, Sponsor: Novartis
Recruiting --> Completed Not yet recruiting --> Completed
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (clinicaltrials.gov) - Jan 12, 2012
P2, N=721, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Surgery: A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery (clinicaltrials.gov) - Jan 10, 2012
P4, N=1300, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: IHPOTOTAM : Induced HyPOthermia TO Treat Adult Meningitis (clinicaltrials.gov) - Jan 8, 2012
P4, N=98, Terminated, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Recruiting --> Terminated; The sponsor stoppes the study for the security problem.
- |||| Trial completion: Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults (clinicaltrials.gov) - Jan 8, 2012
P2, N=51, Completed, Sponsor: Novartis
Recruiting --> Terminated; The sponsor stoppes the study for the security problem. Active, not recruiting --> Completed
- ||| colchicine / Generic mfg.
Trial completion: Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients (clinicaltrials.gov) - Jan 8, 2012
P1, N=75, Completed, Sponsor: Mutual Pharmaceutical Company, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Reducing Health Problems Associated With Injection Drug Use (clinicaltrials.gov) - Jan 2, 2012
P=N/A, N=87, Completed, Sponsor: University of Northern Colorado
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| aztreonam / Generic mfg., vancomycin / Generic mfg., ceftaroline fosamil / Generic mfg.
New P3 trial: Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections (clinicaltrials.gov) - Dec 22, 2011
P3, N=765, Recruiting, Sponsor: AstraZeneca
- || aztreonam / Generic mfg.
Enrollment closed: Registry to Monitor the Susceptibility to Aztreonam of Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients (clinicaltrials.gov) - Dec 22, 2011
P=N/A, N=510, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed Recruiting --> Active, not recruiting
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
New P2 trial: Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) (clinicaltrials.gov) - Dec 21, 2011
P2, N=230, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
- New P1 trial: Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route (clinicaltrials.gov) - Dec 20, 2011
P1, N=24, Completed, Sponsor: University of Oxford
- clindamycin phosphate / Generic mfg.
Clinical: Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Abscess (clinicaltrials.gov) - Dec 19, 2011
P=N/A, N=250, Recruiting, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
- Enrollment change: Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV? (clinicaltrials.gov) - Dec 18, 2011
P=N/A, N=53, Completed, Sponsor: North Shore Long Island Jewish Health System
Recruiting --> Active, not recruiting N=200 --> 53
- Trial completion: Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV? (clinicaltrials.gov) - Dec 18, 2011
P=N/A, N=53, Completed, Sponsor: North Shore Long Island Jewish Health System
N=200 --> 53 Recruiting --> Completed
- Clinical: Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=81, Completed, Sponsor: Hospital Israelita Albert Einstein
- Enrollment open: Prevalence of CVC-associated Sepsis and Use of Blood Cultures in Berlin - Brandenburg (clinicaltrials.gov) - Dec 12, 2011
P=N/A, N=80, Recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| New P3 trial: Immunogenicity and Safety Study of a Three-Dose BioThrax (clinicaltrials.gov) - Dec 12, 2011
P3, N=200, Completed, Sponsor: Emergent BioSolutions
- ||||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
New P4 trial: Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China (clinicaltrials.gov) - Dec 11, 2011
P4, N=900, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||||||| Trial completion: Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine (clinicaltrials.gov) - Dec 11, 2011
P3, N=455, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Trial completion: A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants (clinicaltrials.gov) - Dec 11, 2011
P3, N=1056, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Rotarix (rotavirus vaccine) / GSK
Trial completion: A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar (clinicaltrials.gov) - Dec 11, 2011
P3, N=1375, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (clinicaltrials.gov) - Dec 8, 2011
P2, N=120, Completed, Sponsor: Novartis
Active, not recruiting --> Completed N=80 --> 120
- | ibuprofen / Generic mfg., fosfomycin tromethamine / Generic mfg.
New P4 trial, HEOR: Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI (clinicaltrials.gov) - Dec 6, 2011
P4, N=494, Recruiting, Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
- colchicine / Generic mfg., rifampicin / Generic mfg.
New P2 trial: A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin (clinicaltrials.gov) - Dec 6, 2011
P2, N=2, Completed, Sponsor: Seoul National University Hospital
- Nevanac (nepafenac) / Novartis
Trial withdrawal: Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis (clinicaltrials.gov) - Nov 29, 2011
P2, N=0, Withdrawn, Sponsor: Alcon Research
N=80 --> 120 Not yet recruiting --> Withdrawn
- Nevanac (nepafenac) / Novartis
Enrollment change: Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis (clinicaltrials.gov) - Nov 29, 2011
P2, N=0, Withdrawn, Sponsor: Alcon Research
Not yet recruiting --> Withdrawn N=400 --> 0
- ||| New P1 trial: Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis (clinicaltrials.gov) - Nov 28, 2011
P1, N=60, Completed, Sponsor: JN-International Medical Corporation
- Trial termination: Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA) (clinicaltrials.gov) - Nov 27, 2011
P2, N=8, Terminated, Sponsor: Nitric BioTherapeutics, Inc
N=400 --> 0 Active, not recruiting --> Terminated; Limited recruitment
- ||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change: Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants (clinicaltrials.gov) - Nov 27, 2011
P2, N=200, Completed, Sponsor: Novartis
Active, not recruiting --> Terminated; Limited recruitment N=320 --> 200
- Enrollment change: Clinical Trial on the Reduction of Methicillin Resistant Staphylococcus Aureus (MRSA) (clinicaltrials.gov) - Nov 27, 2011
P2, N=8, Terminated, Sponsor: Nitric BioTherapeutics, Inc
N=320 --> 200 N=20 --> 8
- |||||||||| Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
New P3 trial: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) (clinicaltrials.gov) - Nov 24, 2011
P3, N=1315, Completed, Sponsor: Sanofi Pasteur MSD
- | VPM1002 / SAKK, Serum Institute of India
New P2 trial: Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa (clinicaltrials.gov) - Nov 24, 2011
P2, N=48, Completed, Sponsor: Vakzine Projekt Management GmbH